Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
Life sciences investment firm Westlake launches
by Lisa M. Jarvis
September 9, 2018
| A version of this story appeared in
Volume 96, Issue 36
A new life sciences venture fund, Westlake Village BioPartners, has launched with $320 million to spend on early-stage companies. Westlake was founded by Beth Seidenberg, formerly a partner at the venture capital firm Kleiner Perkins, and Sean Harper, Amgen’s former head of R&D, who will join Westlake in January. Seidenberg brings 12 years of experience incubating biotech firms—many of which went public or were acquired—along with years working at big firms like Amgen, Bristol-Myers Squibb, and Merck & Co.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter